ALK+ Non-Small Cell Lung Cancer

ALNEO Trial of Alectinib for ALK-Positive NSCLC Meets Primary Endpoint
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Advertisement
Advertisement